Clinical Lab Testing / Diagnostic tests / Disease States

New therapeutic approach to combat common STI

New therapeutic approach to combat common STIWith Trichomonas vaginalis being one of the most common STIs in the world, a new therapeutic approach could be developed to help combat the disease.  By using a woman’s natural protective barrier – primarily composed of lactobacilli – it may be possible for the STI to be prevented.

Over 170 million people become infected with Trichomonas each year.  Its growth rate can be attributed the fact that approximately half of those infected do not show symptoms such as irritation, genital inflammation and discharge, and as such pass it on unknowingly.  The parasite can attach itself to the inside of a vagina and damage the cells within it.

Research studies from the University of Auckland in New Zealand investigated how lactobacilli prevents Trichomonas vaginalis from binding to the cells and its subsequent infection.  By using vaginal cells, the researchers tested how easily the parasite bound itself to the cells using different strains of Trichomonas vaginalis and types of lactobacilli.

The results showed that the lactobacilli inhibited the parasite from binding to the cells.  Certain types of lactobacilli were better at preventing binding to the cells, but this was contact dependent.



The CE marked STI array, from Randox Laboratories, Confidante, tests for 10 of the most common sexually transmitted infections.  Through its multiplexing methodology, it allows for excellent precision, specificity, sensitivity and accuracy for STI diagnosis which ultimately results in a reduced risk of false reporting and the number of unnecessary confirmatory tests.



Leave a Reply

Your email address will not be published. Required fields are marked *